Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Existe información en español para pacientes y cuidadores, para acceder, haga clic sobre “Select” al lado de “I am a U.S. Patient / Caregiver”.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

TALZENNA Adverse Reactions (talazoparib)


The following clinically significant adverse reactions are described elsewhere in the labeling:

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Treatment of gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer


The safety of TALZENNA as monotherapy was evaluated in gBRCAm patients with HER2-negative locally advanced or metastatic breast cancer who had previously received no more than 3 lines of chemotherapy for the treatment of locally advanced/metastatic disease. EMBRACA was a randomized, open-label, multi-center study in which 412 patients received either TALZENNA 1 mg once daily (n=286) or a chemotherapy agent (capecitabine, eribulin, gemcitabine, or vinorelbine) of the healthcare provider's choice (n=126) until disease progression or unacceptable toxicity. The median duration of study treatment was 6.1 months in patients who received TALZENNA and 3.9 months in patients who received chemotherapy. Dosing interruptions due to an adverse reaction of any grade occurred in 65% of patients receiving TALZENNA and 50% of those receiving chemotherapy; dose reductions due to any cause occurred in 53% of TALZENNA patients and 40% of chemotherapy patients. Permanent discontinuation due to adverse reactions occurred in 5% of TALZENNA patients and 6% chemotherapy patients.

Table 3 and Table 4 summarize the most common adverse reactions and laboratory abnormalities, respectively, in patients treated with TALZENNA or chemotherapy in the EMBRACA study.

Table 3. Adverse Reactions* (in ≥20% of Patients Receiving TALZENNA) in EMBRACA
N=286 (%)
N=126 (%)
Adverse ReactionsGrades 1–4Grade 3Grade 4Grades 1–4Grade 3Grade 4
Abbreviations: AR=adverse reaction; CTCAE=Common Terminology Criteria for Adverse Events; NCI=National Cancer Institute; N=number of patients.
Graded according to NCI CTCAE 4.03.
Includes anemia, hematocrit decreased, hemoglobin decreased, and red blood cell count decreased.
Includes febrile neutropenia, neutropenia and neutrophil count decreased.
Includes thrombocytopenia and platelet count decreased.
For TALZENNA, Grade 1 in 23%, and Grade 2 in 2%. For the chemotherapy arm, Grade 1 in 20%, and Grade 2 in 8%.
Includes fatigue and asthenia.
Blood and lymphatic system disorders
Metabolism and nutrition disorders
Decreased appetite21<102210
Nervous system disorders
Gastrointestinal disorders
Skin and subcutaneous tissue disorders
General disorders and administration site conditions

The following adverse reactions have been identified in <20% of the 286 patients receiving TALZENNA, and thus were not included in Table 3: abdominal pain (19%), dizziness (17%), leukopenia (17%), dysgeusia (10%), dyspepsia (10%), stomatitis (8%), and lymphopenia (7%).

Table 4 Laboratory Abnormalities Reported in ≥25% of Patients in EMBRACA
N*=286 (%)
N*=126 (%)
ParameterGrades 1–4Grade 3Grade 4Grades 1–4Grade 3Grade 4
Abbreviation: N=number of patients.
This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.
This number represents non-fasting glucose.
Decrease in hemoglobin903907760
Decrease in leukocytes84140.373222
Decrease in neutrophils68173702117
Decrease in lymphocytes76170.75380.8
Decrease in platelets551142920
Increase in glucose54205120
Increase in aspartate aminotransferase37204830
Increase in alkaline phosphatase36203420
Increase in alanine aminotransferase33103720
Decrease in calcium28101600
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event